Edition:
United States

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

1.91USD
20 Apr 2018
Change (% chg)

$0.29 (+17.90%)
Prev Close
$1.62
Open
$1.68
Day's High
$1.91
Day's Low
$1.64
Volume
1,032,302
Avg. Vol
228,584
52-wk High
$2.00
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22
Wednesday, 4 Apr 2018 04:05pm EDT 

April 4 (Reuters) - Eleven Biotherapeutics Inc ::ELEVEN BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING RESULTS AND VICINIUM DEVELOPMENT PROGRESS.Q4 LOSS PER SHARE $0.22.ELEVEN BIOTHERAPEUTICS - NO REV WAS RECOGNIZED DURING QTR ENDED DEC. 31, 2017 VS $0.8 MLN FOR SAME THREE-MONTH PERIOD IN 2016.ELEVEN BIOTHERAPEUTICS INC - EXPECTS TO HAVE CAPITAL TO FUND CURRENT OPERATING PLANS INTO Q1 2019.ELEVEN BIOTHERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE $14.7 MILLION AS OF DECEMBER 31, 2017.  Full Article

Eleven Biotherapeutics To Present Early Data From Bladder Cancer Trial In May
Tuesday, 3 Apr 2018 08:30am EDT 

April 3 (Reuters) - Eleven Biotherapeutics Inc ::PRELIMINARY DATA FROM PHASE 3 VISTA TRIAL IN BLADDER CANCER TO BE PRESENTED IN A PLENARY SESSION AT AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING.ELEVEN BIOTHERAPEUTICS-WITHIN SUBGROUP OF FIRST 75 EVALUABLE PATIENTS, PRELIM FINDINGS SHOW OVER 95 PCT EXPRESSED EPCAM ON SURFACE OF TUMOR CELLS​.ELEVEN BIOTHERAPEUTICS INC - ‍VICINIUM HAS BEEN WELL-TOLERATED​​.  Full Article

Eleven Biotherapeutics Announces Pricing Of $10.0 Million Offering Priced At-The-Market
Wednesday, 21 Mar 2018 09:20am EDT 

Eleven Biotherapeutics Inc ::ELEVEN BIOTHERAPEUTICS ANNOUNCES PRICING OF $10.0 MILLION OFFERING PRICED AT-THE-MARKET.ELEVEN BIOTHERAPEUTICS - ENTERED DEFINITIVE AGREEMENT WITH SEVERAL INVESTORS FOR PURCHASE OF ABOUT 8 MILLION SHARES OF ITS COMMON STOCK AT $1.13PER SHARE.  Full Article

Eleven Biotherapeutics Files For Mixed Shelf Of Upto $150 Mln
Monday, 19 Mar 2018 06:15am EDT 

March 19 (Reuters) - Eleven Biotherapeutics Inc ::ELEVEN BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study
Monday, 12 Mar 2018 06:30am EDT 

March 12 (Reuters) - Eleven Biotherapeutics Inc ::ENROLLMENT COMPLETED IN PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER.ELEVEN BIOTHERAPEUTICS INC - ‍VISTA TRIAL OF VICINIUM IN NMIBC ON-TRACK FOR TOPLINE THREE-MONTH DATA IN MID-2018​.  Full Article

Eleven Biotherapeutics reports Q3 loss per share $0.37
Monday, 20 Nov 2017 08:30am EST 

Nov 20 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics reports third quarter 2017 financial results.Q3 loss per share $0.37.Eleven Biotherapeutics Inc - ‍topline 3-month data from phase 3 trial of Vicinium on track for mid-2018​.Eleven Biotherapeutics - did not record any revenue for three months ended September 30, 2017, compared to revenue of $28.7 million for same period in 2016​.Eleven Biotherapeutics - ‍anticipates cash at Sept 30, net $7.0 million raised in Nov will fund research, development programs, operations into mid-2018​.  Full Article

Eleven Biotherapeutics says expects to report no revenue ‍for 3 months ended Sept 30
Thursday, 16 Nov 2017 09:01am EST 

Nov 16 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics - ‍for 3 months ended Sept 30, co expects to report no revenue compared to $28.7 million in revenue for 3 months ended Sept 30, 2016​.Eleven Biotherapeutics - ‍intends to make accounting adjustments in financial statements in connection with finalization of accounting of Viventia deal ​.  Full Article

Eleven Biotherapeutics CFO steps down; Richard Fitzgerald named interim CFO
Friday, 13 Oct 2017 04:30pm EDT 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics appoints Richard Fitzgerald as interim chief financial officer.Eleven Biotherapeutics Inc - ‍ John McCabe, who currently holds chief financial officer position, will be stepping down​.  Full Article

Eleven Biotherapeutics ‍appoints Richard Fitzgerald as interim CFO
Friday, 13 Oct 2017 04:17pm EDT 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics Inc - ‍appointed Richard F. Fitzgerald, age 54, as company's interim Chief Financial Officer, effective October 13, 2017​.Eleven Biotherapeutics Inc - ‍on October 6, 2017, John J. McCabe resigned as Chief Financial Officer of company, effective as of October 20, 2017​.  Full Article

Eleven Biotherapeutics files for offering of $12.5 mln common stock
Wednesday, 4 Oct 2017 05:28pm EDT 

Oct 4 (Reuters) - Eleven Biotherapeutics Inc :Eleven biotherapeutics inc- files for offering of $12.5 million common stock.  Full Article

BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22

* ELEVEN BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING RESULTS AND VICINIUM DEVELOPMENT PROGRESS